148 related articles for article (PubMed ID: 30589670)
1. Splenic Hemangioma as a Potential Pitfall on PSMA-Targeted 18F-DCFPyL PET/CT.
Chaussé G; Laufer J; Abikhzer G; Probst S
Clin Nucl Med; 2019 Mar; 44(3):255-256. PubMed ID: 30589670
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):546-555. PubMed ID: 31730876
[TBL] [Abstract][Full Text] [Related]
3. Detection of prostate cancer with
Bodar YJL; Jansen BHE; van der Voorn JP; Zwezerijnen GJC; Meijer D; Nieuwenhuijzen JA; Boellaard R; Hendrikse NH; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
World J Urol; 2021 Jul; 39(7):2439-2446. PubMed ID: 33079250
[TBL] [Abstract][Full Text] [Related]
4. Incidental Detection of Splenic Hemangioma on 68Ga-PSMA PET/CT.
Sheng K; Le K; Bui C; Mansberg R
Clin Nucl Med; 2019 Oct; 44(10):821-823. PubMed ID: 31162264
[TBL] [Abstract][Full Text] [Related]
5. False-Positive 18F-PSMA-1007 and True-Negative 18F-Fluorocholine PET/CT Splenic Hemangioma.
Panagiotidis E; Paschali A; Xourgia X; Chatzipavlidou V
Clin Nucl Med; 2020 Dec; 45(12):960-961. PubMed ID: 33065626
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Study on
Rousseau E; Wilson D; Lacroix-Poisson F; Krauze A; Chi K; Gleave M; McKenzie M; Tyldesley S; Goldenberg SL; Bénard F
J Nucl Med; 2019 Nov; 60(11):1587-1593. PubMed ID: 30979820
[No Abstract] [Full Text] [Related]
7. Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.
Cornelis FH; Durack JC; Morris MJ; Scher HI; Solomon SB
Clin Nucl Med; 2017 Dec; 42(12):e516-e518. PubMed ID: 29099733
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of PSMA-based
Mena E; Lindenberg ML; Shih JH; Adler S; Harmon S; Bergvall E; Citrin D; Dahut W; Ton AT; McKinney Y; Weaver J; Eclarinal P; Forest A; Afari G; Bhattacharyya S; Mease RC; Merino MJ; Pinto P; Wood BJ; Jacobs P; Pomper MG; Choyke PL; Turkbey B
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):4-11. PubMed ID: 28894899
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Local Recurrence Detected With Both
Gorin MA; Pienta KJ; Pomper MG; Rowe SP
Urology; 2017 Sep; 107():e9-e10. PubMed ID: 28641974
[TBL] [Abstract][Full Text] [Related]
10. An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Chu LC; Pienta KJ; Pomper MG; Ross AE; Macura KJ
Clin Nucl Med; 2017 Oct; 42(10):e441-e443. PubMed ID: 28806262
[TBL] [Abstract][Full Text] [Related]
11. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted
Werner RA; Sheikhbahaei S; Jones KM; Javadi MS; Solnes LB; Ross AE; Allaf ME; Pienta KJ; Lapa C; Buck AK; Higuchi T; Pomper MG; Gorin MA; Rowe SP
Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739
[TBL] [Abstract][Full Text] [Related]
12. 18F-DCFPyL PET/CT in a Single Large Metastasis With Prostate-Specific Antigen Level of 856 ng/mL.
Wondergem M; Srbljin S; van der Zant FM; Broos WAM; Knol RJJ
Clin Nucl Med; 2019 Oct; 44(10):e588-e589. PubMed ID: 31274553
[TBL] [Abstract][Full Text] [Related]
13. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
14. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
15. Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.
Gomez E; Tran PT; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
Clin Nucl Med; 2019 Apr; 44(4):e313-e314. PubMed ID: 30789396
[TBL] [Abstract][Full Text] [Related]
16. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Werner RA; Bundschuh RA; Bundschuh L; Lapa C; Yin Y; Javadi MS; Buck AK; Higuchi T; Pienta KJ; Pomper MG; Lodge MA; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):190-197. PubMed ID: 31140110
[TBL] [Abstract][Full Text] [Related]
17. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
[TBL] [Abstract][Full Text] [Related]
18. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Sahakyan K; Li X; Lodge MA; Werner RA; Bundschuh RA; Bundschuh L; Kulkarni HR; Schuchardt C; Baum RP; Pienta KJ; Pomper MG; Ross AE; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):181-189. PubMed ID: 31115751
[TBL] [Abstract][Full Text] [Related]
19. Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.
Endepols H; Morgenroth A; Zlatopolskiy BD; Krapf P; Zischler J; Richarz R; Muñoz Vásquez S; Neumaier B; Mottaghy FM
BMC Cancer; 2019 Jun; 19(1):633. PubMed ID: 31242896
[TBL] [Abstract][Full Text] [Related]
20. Correlation of PSMA-Targeted
Tosoian JJ; Gorin MA; Rowe SP; Andreas D; Szabo Z; Pienta KJ; Pomper MG; Lotan TL; Ross AE
Clin Genitourin Cancer; 2017 Feb; 15(1):e65-e68. PubMed ID: 27751686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
